Radiopharmaceuticals

Alcimed worked with a top pharmaceutical client to plan their commercial and logistics strategy for a novel targeted radionuclide.

Across six countries, Alcimed determined in which cancer centers or clinics were most patients treated for three major indications and their level of nuclear medicine capabilities. Alcimed built hypotheses based on the best available data (diagnosis or surgery numbers percenter, presence of a PET scanner or level of accreditation, county-level cancer incidence, etc.) and challenged them during interviews with nuclear medicine physicians, pharmacists, and other stakeholders.

Alcimed deployed an automated approach to map 4000 clinics and hospitals and identify the shortest freight time to potential manufacturing sites through road and air. The exploration of this interactive map with our client helped us validate that even with a limited shelf life, most major cancer sites would be able to receive the drug and treat patients.

This enabled our client to prioritize its commercial efforts in key cities to launch, and also determine a broader market-shaping strategy to overcome capability gaps in key countries.

Alcimed supported a global pharma company to understand the obstacles to treating prostate cancer patient with a novel radiopharmaceutical across major cancer centers.

Based on a full representation of the treatment process from diagnostics to the patient journey within the center for a visit, the role of each stakeholder, Alcimed identified levers to optimize care and increase efficiency. The best practices defined in collaboration with major cancer centers were then deployed across many countries to educate cancer centers.

This increased adoption enabled our client’s commercial and marketing team to feel much closer to their customers and develop this new treatment approach.

Alcimed recently supported a global pharma client to refine its portfolio strategy. PET-PSMA is a novel diagnostic modality using targeted radiopharmaceuticals that can find micrometastases that would have been invisible before.

Alcimed projected the impact of its adoption on patient pathway, disease staging, and the impact on standard of care and prescription behavior of the client’s drugs and competitors.

By looking at the medium term consequences of PET-PSMA, Alcimed recommended a new positioning and specific tactics to leverage the opportunities created by this new standard of care.

Alcimed recently supported a global pharma manufacturer to understand the radiopharmaceutical market and position a production of small batch API.

In this project, our team first explored the needs of potential American customers in terms of API, volume, and purpose to scope our investigation and identify relevant potential partners manufacturers. We therefore then identified and screened European manufacturers, prior to recommend to our client potential manufacturing partners with the right quality and quantity requirement to address each customer segment identified.

Alcimed supported a radiopharmaceutical company in the analysis of the current radiopharmaceutical products order process to identify the potential and required functionalities to develop the company’s own ordering software/tool.

Across six countries, our team conducted interviews with healthcare professionals (HCPs) to understand the current order process and pain points in the use of existing solutions, identify challenges and opportunities for our client, and determine features of interest a new tool should have. Based on the collected data, we were able to define an “ideal” ordering tool for HCPs.

Our project led to significant and actionable insights for the client, revealing existing ordering practices, software, unmet needs, and features of interest to HCPs. As a result, our team recommended developing a new prototype platform to be tested with future key users, guiding our client towards improving their ordering processes and user experience.

Alcimed supported a radiopharmaceutical company in deciphering the landscape of a radiopharmaceutical imaging technique in oncology and in defining concrete levers to maximize the success of the launch and adoption of their new tracer.

Our team conducted an in-depth desk research and targeted interviews with urologists and radiotherapists across public and private healthcare centers in France to understand the PSMA PET imaging landscape and devise actionable strategies for leveraging their support, notably by addressing their current needs on this imaging technique (access, clinical evidence, training and reporting). Subsequently, we defined strategic imperatives based on our client’s priorities and investigation results and validated them during a collaborative working session also held to draft the customer journey.

In the end, our team facilitated determining the feasibility of involving prescribers in the launch of the new tracer and outlined strategies for doing so. Building upon this, we identified two strategic imperatives along with associated key messages to ensure prescribers engagement, as well as tangible operational levers of engagement.

We helped a leading pharmaceutical company to develop a strategy for the launch of two new radiopharmaceutical products.

To this end, our teams carried out an in-depth analysis of competing radiopharmaceutical treatments and their use on the market (profiles of patients and specialists prescribing them, typology of centers using them). This analysis highlighted the obstacles to prescribing, the expected results of these treatments, and enabled the identification of the differentiating features of our customer’s products. Finally, we analyzed the economic potential of radiopharmaceutical treatments (level of reimbursement, average cost per patient, etc.) and defined a positioning consistent with market reality and our customer’s objectives.

Ultimately, our project enabled our client to define its clinical development roadmap for its two radiopharmaceutical products, their strategic positioning and an appropriate commercial strategy for launching them on the market.

We supported a leading pharmaceutical company in developing a business case to optimize access and adoption of a radiopharmaceutical product. Our client was facing numerous logistical constraints in US treatment centers, severely limiting access to its product.

To develop this business case, our teams mapped and ranked treatment centers in the U.S., identifying the most promising based on their ability to use our customer’s radiopharmaceutical product. We designed an interactive tool to visualize these centers and prioritize them according to criteria such as potential patient volume, for example. This analysis also enabled us to target centers where specific actions could be implemented to alleviate logistical constraints and maximize product adoption.

At the end of the project, our customer was able to structure the assumptions of its business case, including a realistic number of centers to target and an estimate of the volume of patients concerned. We also co-defined concrete steps and priority actions to be implemented to improve access and adoption of his radiopharmaceutical product on the US market.